顽固性心力衰竭病情较重,病死率很高,而且治疗上十分棘手。左西孟旦系新型抗心力衰竭药物之一,已广泛用于治疗急慢性充血性心力衰竭。既往关于重复或间隙使用左西孟旦对治疗顽固性心力衰竭的效果尚不清楚,现就此进行相关汇总对照分析。作者检索了2015年6月以前的Central、Medline、Pubmed及Cochrane等相关数据库文献,共检索出完全符合条件的且资 Severe illness refractory heart failure, high mortality, but also very difficult to treat. Levosimendan is one of the novel anti-heart failure drugs that have been widely used in the treatment of acute and chronic congestive heart failure. The past on the repeated or interstitial use of levosimendan in the treatment of refractory heart failure is not yet clear, this is the relevant summary of the control analysis. The authors searched Central, Medline, Pubmed, and Cochrane database databases prior to June 2015 for a total search of fully qualified